Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»BioTech»DCH Auriga selected as the logistics partner to distribute the Fosun Pharma BioNTech COVID-19 vaccine in Hong Kong
    BioTech

    DCH Auriga selected as the logistics partner to distribute the Fosun Pharma BioNTech COVID-19 vaccine in Hong Kong

    Marie JonesBy Marie JonesJanuary 28, 2021Updated:January 29, 2021No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    DCH Auriga, one of the largest healthcare distributors in Hong Kong with decades of experience managing sophisticated pharmaceutical supply chains, is pleased to announce it has been selected to manage the storage and delivery of the Fosun Pharma BioNTech BNT162b2 vaccine in Hong Kong as the exclusive logistics partner of Shanghai Fosun Pharmaceutical (Group) Co., Limited (Stock Code: 600196.SH, 02196.HK) and Jacobson Pharma Corporation Limited (Stock Code: 2633).

    Under the agreement, DCH Auriga Hong Kong Ltd. will leverage its specialty cold chain expertise and unique healthcare-dedicated infrastructure to provide Ultra Low Temperature storage and distribution for the safe and timely supply of the COVID-19 vaccine.

    Tim Collins, the CEO of DCH Auriga said, “We are honoured to support this vital vaccination program and play a part in protecting the health and well-being of our communities. As long-time partners of the public health system and specialists in cold chain distribution for the healthcare industry, we are well experienced in handling Ultra Low temperature requirements with highly trained staff and robust quality assurance protocols. We are confident in our ability to deliver this vaccine safely and securely, in full accordance with the directives of the Government and Department of Health.”

    DCH Auriga
    DCH Auriga, a subsidiary of Dah Chong Hong Holdings Limited, is an Asia-based market management provider specialising in healthcare. Offering comprehensive commercial and logistics solutions, DCH Auriga partners with the world’s leading healthcare companies to distribute pharmaceuticals, medical devices, surgical equipment, diagnostics and OTC products for more than 500 brands into hospitals, pharmacies and specialty stores across Asia. DCH Auriga has operations in Hong Kong, Macao, mainland China, Singapore, Malaysia, Indonesia, Thailand and the Philippines.

    For more details, please visit www.dchauriga.com.

    Dah Chong Hong Holdings, an indirect wholly owned subsidiary of CITIC Limited (stock code: 0267.HK), is an integrated trading and distribution company operating in Asia, supported by an extensive logistics network. DCH is a leading distributor and dealer of motor vehicles in Greater China as well as a provider of a full range of associated services. DCH’s consumer business comprises the manufacture and distribution of food, healthcare, electrical appliances, beauty and lifestyle products. DCH employs over 16,500 staff with operations in 12 Asian markets.

    For more details, please visit www.dch.com.hk.

    Media Enquires:
    DCH Communications | (852) 2768 2017 | dchcommunications@dch-holdings.com

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleChina Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter
    Next Article Blockpass Provides Powerful On-chain KYC(TM) Utility for EasyFi DeFi Lending Platform

    Related Posts

    Micot’s XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease

    October 5, 2026

    Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China’s NMPA, Driving Continued Commercial Momentum

    October 2, 2026

    ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines’ CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment Option

    September 21, 2026
    Add A Comment

    Comments are closed.

    Latest News

    • Stagwell Launches New Global Media Agency, Stagwell Media
    • U.S. Polo Assn. Celebrates an Outstanding 2026 European Polo Season
    • JCB Launches Premium Card Issuing Initiative for Affluent Customers in ASEAN Under Strategic Comprehensive Partnership with MUFG Bank
    • TMX Group Thanksgiving Holiday Market Closures
    • Chervon Names Claudio Chiappetta Vice President of Retail Sales for Chervon Canada
    • Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon Canada
    • Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts
    • TIPAK Marks Path to Leadership in Packaging Solutions Following Listing on SET
    • Chervon Names Daniel L. Abbott Director of Sales – Western U.S.A.
    • Micot’s XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease
    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.